Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

[1]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[2]  M. Hogarty.  The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. , 2003, Cancer letters.

[3]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[4]  E. Olson,et al.  Twist Regulates Cytokine Gene Expression through a Negative Feedback Loop that Represses NF-κB Activity , 2003, Cell.

[5]  Birgit Luber,et al.  Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. , 2002, The American journal of pathology.

[6]  R. Behringer,et al.  Twist plays an essential role in FGF and SHH signal transduction during mouse limb development. , 2002, Developmental biology.

[7]  V. El Ghouzzi,et al.  Twist haploinsufficiency in Saethre-Chotzen syndrome induces calvarial osteoblast apoptosis due to increased TNFalpha expression and caspase-2 activation. , 2002, Human molecular genetics.

[8]  P. Catalano,et al.  c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. , 2001, Cancer research.

[9]  L. Kedes,et al.  Twist is a potential oncogene that inhibits apoptosis. , 1999, Genes & development.

[10]  M. Schwab,et al.  MycN sensitizes neuroblastoma cells for drug-induced apoptosis , 1999, Oncogene.

[11]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[12]  L. Kedes,et al.  The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein, Twist , 1997, Molecular and cellular biology.

[13]  M. Schwab,et al.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. , 1996, Oncogene.

[14]  L. Donehower,et al.  The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. , 1995, Oncogene.

[15]  R. Behringer,et al.  twist is required in head mesenchyme for cranial neural tube morphogenesis. , 1995, Genes & development.

[16]  E. Füchtbauer,et al.  M-twist is an inhibitor of muscle differentiation. , 1994, Developmental biology.

[17]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[18]  J. Pelletier,et al.  Absence of p53 gene mutations in primary neuroblastomas. , 1993, Cancer research.

[19]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[20]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[21]  M. Leptin,et al.  Cell shape changes during gastrulation in Drosophila. , 1990, Development.

[22]  H. Varmus,et al.  Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture , 1985, Nature.

[23]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[24]  E. Green,et al.  Mutations in TWIST, a basic helix–loop–helix transcription factor, in Saethre-Chotzen syndrome , 1997, Nature Genetics.

[25]  P. Bénit,et al.  Mutations of the TWIST gene in the Saethre-Chotzene syndrome , 1997, Nature Genetics.

[26]  E. Olson,et al.  bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. , 1994, Genes & development.